The commonly reported gastrointestinal side effects-that occur with erythromycin are related to its prokinetic action on the gut, mediated, at least in part, by its motilin receptor stimulating activity. This action may be of clinical use in conditions associated with gastrointestinal hypomotility such as diabetic gastroparesis and intestinal pseudo-obstruction, although further work needs to be done to establish the long term therapeutic uses of erythromycin in these disorders. Macrolide compounds with no antibacterial properties but which have a pronounced prokinetic action on the gut have already been synthesised and are currently being developed for future use in man. These 'motilides' should provide a useful addition to our rather limited armamentarium of effective gastrointestinal prokinetic agents.
Since the introduction of erythromycin into clinical practice, gastrointestinal side effects, commonly nausea and vomiting, cramping upper abdominal pain, and diarrhoea, have been consistently reported. Erythromycin, as far as we know, uniquely among antibiotics, is a motilin receptor agonist with a profound effect on gastroduodenal motor activity. It is this action which is accountable for many of its unwanted effects on the gut. More importantly, the prokinetic action of erythromycin and related molecules may be clinically useful in conditions associated with gastrointestinal hypomotility such as diabetic gastroparesis and idiopathic pseudo-obstruction. In this review the available evidence on the mode of action of erythromycin on the gastrointestinal tract will be outlined together with the results of studies supporting a potential clinical role in conditions associated with gastrointestinal hypomotility.
Gastrointestinal side effects associated with erythromycin Erythromycin, originally isolated from an actinomycete in a soil sample from the Philippines' and purified and used clinically by McGuire et al in 1952,2 has become established as a safe and useful antibiotic with a broad spectrum of action against many commonly acquired bacterial pathogens. Although remarkably free from serious adverse reactions, it has long been associated with gastrointestinal side effects such as nausea, vomiting, and diarrhoea. Although initial reports suggested that these side effects only occurred in 7 to 10% of subjects given oral erythromycin,' recent studies suggest that this is an underestimate with up to 95% of subjects receiving intravenous erythromycin and 51% of subjects given oral erythromycin I 5 g for dental prophylaxis experiencing gastrointestinal symptoms.3 In a study of 10 subjects given 800 mg erythromycin lactobionate intravenously, eight subjects experienced stomach discomfort, six were nauseated, and one vomited. There was a significant correlation between severity of symptoms, infusion rate, and plasma erythromycin concentration.6
Erythromycin and gastrointestinal motility The propensity of erythromycin to produce gastrointestinal side effects is often rather vaguely ascribed to its antibiotic properties producing a change in intestinal flora. However, two studies reported in 1984 indicated that erythromycin has a direct effect on Other sites of action of erythromycin on the gastrointestinal tract Since the description ofthe effect oferythromycin on antroduodenal motor activity, other areas of the gastrointestinal tract have been studied. The ability of erythromycin to cause motor contraction varies from one region of the gut to another and in the rabbit, at least, this variability has been shown to correlate with motilin receptor concentration. 12 13 Erythromycin increases lower oesophageal sphincter pressure in man in the fasting and fed state, but has no effect on oesophageal body peristalsis.' 1'1 The effect of erythromycin on the lower oesophageal sphincter can be blocked by atropine, suggesting that it is vagally mediated. 11 Colonic motor activity in the rabbit is stimulated in vitro by erythromycin." Erythromycin induced strong contractions in proximal colonic muscle strips which became less pronounced distally until strong contractions were again induced in the most distal part of the colon. Binding studies with homogenates of colonic smooth muscle incubated with radiolabelled motilin showed significantly more binding sites in the distal than in the proximal colon. As in other areas of the gut, erythromycin binds to motilin receptors in the rabbit colon."' Using ingested radio-opaque markers these authors showed that oral erythromycin reduces transit time in the right colon in human volunteers. The subjects also noted an increase in stool frequency.
Interdigestive gall bladder motility in many species, including man, is related to antroduodenal motor activity, the 26 These studies suggest that the molecular structure of the macrolide is critical in determining its ability to stimulate gastrointestinal motor activity and that a 14-membered lactone ring and a dimethylaminosugar at C-S and neutral sugar at C-3, in glycosidic linkage are vital in conferring MMC stimulating activity. Although the difference in structure between erythromycin and oleandomycin is small, with variation only in the radicals bound at C-8, this seems to be important in determining the ability to cause gastrointestinal contraction. Intravenous infusion of oleandomycin, like erythromycin (but not the 16-membered macrolides) significantly raised plasma motilin concentrations in the dog26 suggesting that the 14-membered but not the 16-membered macrolides were able to stimulate gastrointestinal motor activity by inducing the release of endogenous motilin.
The motilin receptor has not yet been isolated and nothing is known about its structure. Motilin, a 22 amino acid peptide, has been sequenced and although the amino acids involved in binding to the receptor have not been identified, studies of the contractile effects of motilin fragments suggest that both the NH2-and COOH-terminals are necessary to activate the receptor.27 The molecular structure of erythromycin is very different to that of motilin yet their spatial configuration and charge distribution must be similar in order to activate the same receptor.
In vivo studies in dogs showing that erythromycin releases endogenous motilin do not contradict the evidence that erythromycin is a motilin receptor agonist; it is known that motilin can induce its own release and presumably binding of erythromycin to the receptor can have the same effect.
Evidence that erythromycin is not solely a motilin receptor agonist Despite good evidence that erythromycin acts as a motilin receptor agonist, the effect of erythromycin on small bowel motor activity is not completely analogous to that of motilin." Unlike erythromycin, exogenously administered motilin, even in high doses, has been reported to initiate only a premature MMC. It does not affect cycle length or inhibit the MMC in progress. Erythromycin also causes other motor effects, retrograde giant contractions and clustered duodenal contractions, which have not been described with motilin. Furthermore, there are significant species differences between the in vitro and in vivo data. Erythromycin has a pronounced effect on canine duodenal muscle in the intact animal2829 but no effect on canine muscle strips.'223 The contractions produced by erythromycin on muscle strips cannot be blocked by tetrodotoxin or atropine, 21 in contrast to the in vivo situation where both the actions of erythromycin and motilin are inhibited by atropine. "33 There is some evidence that erythromycin has actions on neuromuscular transmission and cellular electrical activity; erythromycin given to normal subjects produces myasthenic like changes in neuromuscular transmission on electromyography but without clinical weakness.34 These changes could be reversed by edrophonium suggesting that erythromycin has a presynaptic action at the neuromuscular junction. Recently, a patient has been described with myasthenia gravis whose symptoms were worsened by erythromycin.3" The effect of erythromycin on the ECA of the small bowel with consequent disruption of motor activity might be related to an effect on the cholinergic intrinsic neurones which are thought to be important in the control of the ECA. Erythromycin also has an effect on the cardiac action potential; intravenous The effect of erythromycin in other situations where gastrointestinal motility is impaired has since been examined and although thus far the studies reported are small or only anecdotal, there is an accumulation of evidence that the promotility actions of erythromycin will be useful in a variety of clinical situations. A dose of 250 mg oral erythromycin before each meal returned gastric emptying to normal in a patient with postvagotomy gastroparesis and this improvement was maintained over eight months' therapy.39 Two patients with Ogilvie's syndrome (reflex ileus) were treated successfully with oral erythromycin.'
The effect of intravenous erythromycin on gastrointestinal motility in eight patients with chronic idiopathic intestinal pseudo-obstruction has also been studied.4' Erythromycin induced phase III motor contractions in all the patients. The usefulness of long term erythromycin in these subjects, and more importantly the effect on symptoms, has not been established. Erythromycin has not so far been reported as a potential prokinetic agent in visceral aganglionosis but it might be anticipated that it is more likely to be helpful in situations where the neural circuitry is preserved, such as intestinal myopathies. Whether current tests of motility are of help in predicting clinical response to erythromycin (or other prokinetic agents) is as yet unclear.
The prokinetic actions of erythromycin have also been put to good use in the siting of naso-or oroduodenal tubes as erythromycin enhances the transit of the tube through the pylorus. 
